Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study.

Abstract	In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer).
Authors	Kelly Marie Gollar, Douglas G Young, James Bailen, Weizhong He, Sergio Forero-Schwanhaeuser
Journal	Urologic nursing (Urol Nurs) 2012 Jan-Feb Vol. 32 Issue 1 Pg. 38-46, 50 ISSN: 1053-816X [Print] United States
PMID	22474864 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Muscarinic Antagonists Quinuclidines Tetrahydroisoquinolines Solifenacin Succinate
Topics	Adult Female Humans Male Muscarinic Antagonists (therapeutic use) Patient Satisfaction Quality of Life Quinuclidines (therapeutic use) Randomized Controlled Trials as Topic Self Report Solifenacin Succinate Tetrahydroisoquinolines (therapeutic use) Treatment Outcome Urinary Bladder, Overactive (drug therapy, nursing, psychology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!